Novel mouse hemostasis model for real-time determination of bleeding time and hemostatic plug composition

Journal of Thrombosis and Haemostasis

Volumn 13, Issue 3, 2015, Pages 417-425

  Getz, T M ^a   Piatt, R ^a   Petrich, B G ^b   Monroe, D ^a   Mackman, N ^a   Bergmeier, W ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Blood coagulation; Blood platelets; Fluorescence imaging; Hemostasis; Mice

Indexed keywords

BLOOD CLOTTING FACTOR 9; CLOPIDOGREL; GLYCOPROTEIN IB ALPHA; PROTEIN; TALIN 1 PROTEIN; THROMBOPLASTIN; UNCLASSIFIED DRUG; ADHESION RECEPTOR; ANTITHROMBOCYTIC AGENT; FIBRIN; TALIN; TALIN PROTEIN, MOUSE; THROMBIN RECEPTOR; TICLOPIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLEEDING TIME; CONTROLLED STUDY; EXPERIMENTAL MOUSE; FIBRIN FORMATION; FLUORESCENCE MICROSCOPY; GLYCOPROTEIN IB ALPHA DEFICIENT MOUSE; HEMOSTASIS; LASER SURGERY; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SAPHENOUS VEIN; TALIN 1 DEFICIENT MOUSE; THROMBOCYTE ADHESION; VEIN INJURY; WILD TYPE MOUSE; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; BLOOD CLOTTING; C57BL MOUSE; DEFICIENCY; DISEASE MODEL; DRUG EFFECTS; GENETICS; INTRAVITAL MICROSCOPY; KNOCKOUT MOUSE; LOW LEVEL LASER THERAPY; METABOLISM; SURGERY; THROMBOCYTE; TIME FACTOR; VASCULAR SYSTEM INJURIES; VIDEO MICROSCOPY;

ANIMALS; BLEEDING TIME; BLOOD COAGULATION; BLOOD PLATELETS; DISEASE MODELS, ANIMAL; FACTOR IX; FIBRIN; HEMOSTASIS; INTRAVITAL MICROSCOPY; LASER THERAPY; MICE, INBRED C57BL; MICE, KNOCKOUT; MICROSCOPY, FLUORESCENCE; MICROSCOPY, VIDEO; PLATELET ADHESIVENESS; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIB-IX COMPLEX; SAPHENOUS VEIN; TALIN; THROMBOPLASTIN; TICLOPIDINE; TIME FACTORS; VASCULAR SYSTEM INJURIES;

EID: 84923810710     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12802     Document Type: Article

References (33)

1. Broos K, Feys HB, De Meyer SF, Vanhoorelbeke K, Deckmyn H. Platelets at work in primary hemostasis. Blood Rev 2011; 25: 155-67.
2. Shattil SJ, Kim C, Ginsberg MH. The final steps of integrin activation: the end game. Nat Rev Mol Cell Biol 2010; 11: 288-300.
3. Petrich BG, Marchese P, Ruggeri ZM, Spiess S, Weichert RAM, Ye F, Tiedt R, Skoda RC, Monkley SJ, Critchley DR, Ginsberg MH. Talin is required for integrin-mediated platelet function in hemostasis and thrombosis. J Exp Med 2007; 204: 3103-11.
4. Nieswandt B, Moser M, Pleines I, Varga-Szabo D, Monkley S, Critchley D, Fassler R. Loss of talin1 in platelets abrogates integrin activation, platelet aggregation, and thrombus formation in vitro and in vivo. J Exp Med 2007; 204: 3113-18.
5. Savage B, Almus-Jacobs F, Ruggeri ZM. Specific synergy of multiple substrate-receptor interactions in platelet thrombus formation under flow. Cell 1998; 94: 657-66.
6. Bergmeier W, Piffath CL, Goerge T, Cifuni SM, Ruggeri ZM, Ware J, Wagner DD. The role of platelet adhesion receptor GPIbalpha far exceeds that of its main ligand, von Willebrand factor, in arterial thrombosis. Proc Natl Acad Sci USA 2006; 103: 16900-5.
7. Kanaji T, Russell S, Ware J. Amelioration of the macrothrombocytopenia associated with the murine Bernard-Soulier syndrome. Blood 2002; 100: 2102-7.
8. Mackman N. The role of tissue factor and factor VIIa in hemostasis. Anesth Analg 2009; 108: 1447-52.
9. Parry GC, Ehrlich JH, Carmeliet P, Luther T, Mackman N. Low levels of tissue factor are compatible with development and hemostasis in mice. J Clin Invest 1998; 101: 560-9.
10. Sixma JJ, van den Berg A. The haemostatic plug in haemophilia A: a morphological study of haemostatic plug formation in bleeding time skin wounds of patients with severe haemophilia A. Br J Haematol 1984; 58: 741-53.
11. Satta N, Toti F, Fressinaud E, Meyer D, Freyssinet JM. Scott syndrome: an inherited defect of the procoagulant activity of platelets. Platelets 1997; 8: 117-24.
12. Bi L, Lawler AM, Antonarakis SE, High KA, Gearhart JD, Kazazian HH. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nat Genet 1995; 10: 119-21.
13. Lin HF, Maeda N, Smithies O, Straight DL, Stafford DW. A coagulation factor IX-deficient mouse model for human hemophilia B. Blood 1997; 90: 3962-6.
14. Gailani D, Lasky NM, Broze GJ. A murine model of factor XI deficiency. Blood Coagul Fibrinolysis 1997; 8: 134-44.
15. Thijs T, Deckmyn H, Broos K. Model systems of genetically modified platelets. Blood 2012; 119: 1634-42.
16. Nakanishi-Matsui M, Zheng YW, Sulciner DJ, Weiss EJ, Ludeman MJ, Coughlin SR. PAR3 is a cofactor for PAR4 activation by thrombin. Nature 2000; 404: 609-13.
17. McKenzie SE. Humanized mouse models of FcR clearance in immune platelet disorders. Blood Rev 2002; 16: 3-5.
18. Hayashi T, Nishioka J, Kamada H, Asanuma K, Kondo H, Gabazza EC, Ido M, Suzuki K. Characterization of a novel human protein C inhibitor (PCI) gene transgenic mouse useful for studying the role of PCI in physiological and pathological conditions. J Thromb Haemost 2004; 2: 949-61.
19. Wood JP, Ellery PER, Maroney SA, Mast AE. Biology of tissue factor pathway inhibitor. Blood 2014; 123: 2934-43.
20. Greene TK, Schiviz A, Hoellriegl W, Poncz M, Muchitsch EM. Animal models subcommittee of the Scientific and Standardization Committee of the ISTH. Towards a standardization of the murine tail bleeding model. J Thromb Haemost 2010; 8: 2820-2.
21. ®)). Haemophilia 2012; 18: 782-8.
22. Stefanini L, Ye F, Snider AK, Sarabakhsh K, Piatt R, Paul DS, Bergmeier W, Petrich BG. A talin mutant that impairs talin-integrin binding in platelets decelerates αIIbβ3 activation without pathological bleeding. Blood 2014; 123: 2722-31.
23. Stolla M, Stefanini L, Roden RC, Chavez M, Hirsch J, Greene T, Ouellette TD, Maloney SF, Diamond SL, Poncz M, Woulfe DS, Bergmeier W. The kinetics of alphaIIbbeta3 activation determines the size and stability of thrombi in mice: implications for antiplatelet therapy. Blood 2011; 117: 1005-13.
24. Baumgartner B, Jaki T, Wolfsegger MJ, Eder B, Schiviz A, Schwarz HP, Muchitsch EM. Optimization, refinement and reduction of murine in vivo experiments to assess therapeutic approaches for haemophilia A. Lab Anim 2010; 44: 211-17.
25. Westrick RJ, Winn ME, Eitzman DT. Murine models of vascular thrombosis. Arterioscler Thromb Vasc Biol 2007; 27: 2079-93.
26. Denis CV, Wagner DD. Platelet adhesion receptors and their ligands in mouse models of thrombosis. Arterioscler Thromb Vasc Biol 2007; 27: 728-39.
27. Barr JD, Chauhan AK, Schaeffer GV, Hansen JK, Motto DG. Red blood cells mediate the onset of thrombosis in the ferric chloride murine model. Blood 2013; 121: 3733-41.
28. van Gestel MA, Heemskerk JWM, Slaaf DW, Heijnen VVT, Sage SO, Reneman RS, oude Egbrink MGA. Real-time detection of activation patterns in individual platelets during thromboembolism in vivo: differences between thrombus growth and embolus formation. J Vasc Res 2002; 39: 534-43.
29. van Gestel MA, Heemskerk JWM, Slaaf DW, Heijnen VVT, Reneman RS, oude Egbrink MGA. In vivo blockade of platelet ADP receptor P2Y12 reduces embolus and thrombus formation but not thrombus stability. Arterioscler Thromb Vasc Biol 2003; 23: 518-23.
30. George JN. Platelets. Lancet 2000; 355: 1531-9.
31. Broze GJ, Yin ZF, Lasky N. A tail vein bleeding time model and delayed bleeding in hemophiliac mice. Thromb Haemost 2001; 85: 747-8.
32. Pawlinski R, Pedersen B, Erlich J, Mackman N. Role of tissue factor in haemostasis, thrombosis, angiogenesis and inflammation: lessons from low tissue factor mice. Thromb Haemost 2004; 92: 444-50.
33. Kaneshiro MM, Mielke CH, Kasper CK, Rapaport SI. Bleeding time after aspirin in disorders of intrinsic clotting. N Engl J Med 1969; 281: 1039-42.